Moderna (MRNA)
(Delayed Data from NSDQ)
$107.97 USD
+1.79 (1.69%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $107.85 -0.12 (-0.11%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Price, Consensus and EPS Surprise
MRNA 107.97 +1.79(1.69%)
Will MRNA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MRNA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MRNA
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing
Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
MRNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Analysts Estimate Moderna (MRNA) to Report a Decline in Earnings: What to Look Out for
Is First Trust NASDAQ-100 Equal Weighted ETF (QQEW) a Strong ETF Right Now?
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
Other News for MRNA
MRNA June 2026 Options Begin Trading
Cantor Fitzgerald biopharma analyst holds analyst/industry conference call
Cantor Fitzgerald biopharma analyst holds analyst/industry conference call
What's Going On With Pfizer Stock On Thursday?
GSK sues Pfizer, BioNTech over COVID-19 vaccines patents